Willis-Ekbom disease


Also found in: Medical, Wikipedia.

Wil·lis-Ek·bom disease

(wĭl′ĭs-ĕk′bəm)
[After Thomas Willis (1621-1675), English physician, and Karl-Axel, Ekbom (1907-1977), Swedish neurologist.]
Mentioned in ?
References in periodicals archive ?
People with Willis-Ekbom Disease or Restless Legs Syndrome (RLS) are likely to be at a greater risk of suicide, suicidal thoughts and self-harm, a study claimed.
Willis-Ekbom disease, is a surprisingly common condition that causes an unpleasant or uncomfortable feeling in the limbs -- particularly at night -- and an overwhelming urge to move them.
According to the National Institute of Neurological Disorders and Stroke, RLS or Restless Leg Syndrome is also called Willis-Ekbom Disease which causes uncomfortable sensations in the legs and an irresistible urge to move them which usually occur late afternoon or evening.
The relationship between Willis-Ekbom disease and serum ferritin levels among children in Northwestern Turkey.
Restless leg syndrome, also called the Willis-Ekbom disease, is a common neurological sensoriomotor disorder characterized by an unpleasant or uncomfortable urge to move the legs; it occurs during rest, particularly in the evenings, and is transiently relieved by movement.
Restless legs syndrome (RLS), also named Willis-Ekbom disease, is a frequent neurological disease that is characterized by paresthesias and unpleasant sensations in the legs and an urge to move the legs (1,2).
RLS was first reported in 1945 by Ekbom1 and is also known as Willis-Ekbom Disease (WED).
A Also known as Willis-Ekbom Disease, restless legs syndrome (RLS) affects as many as one in 10 American adults, according to the National Sleep Foundation.
Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG; Medical Advisory Board of the Willis-Ekbom Disease Foundation.
RLS, which is also known as Willis-Ekbom Disease, is a common sleep disorder characterised by a strong urge to move the legs at night.
The new credit facility will support the company's ongoing operations as it launches its Relaxis system, a non-pharmacologic solution for improving the quality of sleep in patients with primary restless leg syndrome (RLS), a progressive neurological condition also known as Willis-Ekbom Disease (WED).